At the news
? BULLISHIMPACT 7/10 8-K filed Feb 26, 2026 at 06:35 ET
Nuvalent reported its 2025 financial results, highlighted a strong cash position of $1.4 billion with runway into 2029, and provided updates on its drug development pipeline. Key milestones include FDA acceptance of the NDA for zidesamtinib with a PDUFA date of September 18, 2026, and plans for neladalkib NDA submission in the first half of 2026. The company also completed a $500 million public offering in November 2025.
- Cash, cash equivalents and marketable securities were $1.4 billion as of December 31, 2025
- FDA accepted NDA for zidesamtinib with PDUFA target action date of September 18, 2026
- Completed $500 million public offering of common stock in November 2025
- R&D expenses were $307.0 million for full year 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access